This site is intended for UK Healthcare professionals only

Are you a UK Healthcare professional?

We are unfortunately unable to allow patients to attend the Best Practice Show

If you would like more information on general practice or primary care, please refer to the NHS website.

Visit the NHS website?

Co-Located Events

Best Practice Programme 2023

Subpage Hero



Understanding SGLT2 inhibitors

12 Oct 2023
Best Practice in Diabetes Theatre
SGLT2 inhibitors (SGLT2-Is) are a class of antidiabetic drugs that work by inhibiting the sodium-glucose co-transporter 2 in the kidneys, reducing glucose reabsorption and promoting glycosuria. Recently, evidence has emerged supporting their use in chronic kidney disease (CKD) and heart failure. SGLT2-Is have demonstrated significant benefits in slowing CKD progression, reducing cardiovascular events, and improving heart failure outcomes, making them valuable therapeutic options for patients with these conditions.
Samuel Seidu, Professor of Primary Care Diabetes and Cardiometabolic Medicine - University of Leicester, Hockley Farm MP, Leicester City CCG

Newsletter Sign Up